汇宇制药跌4.26% 上半年亏损2021上市即巅峰募24.7亿

Core Viewpoint - Huyou Pharmaceutical (688553.SH) is currently experiencing a decline in stock price, having closed at 22.91 yuan, down 4.26% from previous levels [1] Group 1: Company Overview - Huyou Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 26, 2021, with an initial public offering of 63.6 million shares at a price of 38.87 yuan per share [1][2] - The total funds raised from the IPO amounted to 2.472 billion yuan, with a net amount of 2.361 billion yuan after deducting issuance costs, which was 453 million yuan more than the original plan of 1.907 billion yuan [2] Group 2: Financial Performance - From 2021 to 2023, the company's operating revenues were 1.824 billion yuan, 1.493 billion yuan, and 927 million yuan, respectively. The net profits attributable to shareholders were 446 million yuan, 249 million yuan, and 140 million yuan, respectively [3] - In 2024, the company achieved an operating revenue of 1.094 billion yuan, representing an 18.05% year-on-year increase, with a net profit of 325 million yuan, up 132.78% [3] - For the first half of 2025, the company reported an operating revenue of 453 million yuan, a decrease of 14.86% year-on-year, and a net loss of 80.72 million yuan, compared to a profit of 65.21 million yuan in the same period last year [4]